IgA nephropathy in pediatric patients, clinical outcomes with three types of management
PDF (Español)
XML (Español)


Glomerulonephritis, IGA; children; hematuria; proteinuria; Purpura, Schoenlein-Henoch; vasculitis.

How to Cite

Forero-Delgadillo J, Torres-Canchala L, Duque N, Galvis-Blanco L, Lasso R, Aguirre J, Jimenez C, Arrunategui AM, Londoño H, Restrepo JM. IgA nephropathy in pediatric patients, clinical outcomes with three types of management: Nefropatía por inmunoglobulina A en pediatría, desenlaces clínicos con diferentes esquemas de manejo. Rev. Colomb. Nefrol. [Internet]. 2020 Nov. 5 [cited 2024 Apr. 20];8(1):e422. Available from: https://revistanefrologia.org/index.php/rcn/article/view/422


IgA nephropathy (IgAN) is the most common glomerular disease in the world, in Colombia belongs to 11-22 % of primary glomerulonephritis in pediatric patients. Of these, 30 % progress to chronic kidney disease.

Materials and methods:
It is a retrospective descriptive study. We used median and IRQ for continuous variables, and proportions for categorical variables, Fisher test to compare clinical outcomes.

Between 1996 to 2013 58 patients were diagnosed. The mean age at symptoms onset was 7.5 years (SD±4.2) and at the time of renal biopsy was 10 years (SD±3.8). At diagnosis, 77.6 % of the patients showed microscopic hematuria, 27.6 % gross hematuria and 81 % proteinuria, classified as severe in 29 %. Three patients required dialysis and two needed kidney transplant. Three groups with different therapeutic regimens were evaluated: first group only prednisone 34.5 % (n= 20), second group prednisone and mycophenolate mofetil (MMF) 22.4 % (n = 13) and third group without prednisone neither MMF 43.1 % (n =25). The difference in the presence of hematuria among the groups was significant (p> 0.001), being more frequent in the group without prednisone neither MMF (68 %). There were no significant differences in proteinuria, hypertension or creatinine among the groups. The median of years between the renal biopsy and the last control was 4 years RI 1-7. At five years, the renal function survival probability (GFR >90 ml/min/1.73m2) was 89.1 %.

IgAN needs early recognition and strict follow-up, since it may have ominous outcomes.

PDF (Español)
XML (Español)


Hogg RJ. Idiopathic immunoglobulin a nephropathy in children and adolescents. Vol. 25, Pediatric Nephrology. Springer; 2010. p. 823-9. https://doi.org/10.1007/s00467-008-1096-3

D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987 Sep;64(245):709-27.

Nair R, Walker PD. Is IgA nephropathy the commonest primary glomerulopathy among young adults in the USA? Kidney Int. 2006 Apr;69(8):1455-8. https://doi.org/10.1038/sj.ki.5000292

Prada Rico M, Rodríguez Cuellar CI, Fernandez Hernandez M, González Chaparro LS, Prado Agredo OL, Gastelbondo Amaya R. Characterization and etiopathogenic approach of pediatric renal biopsy patients in a colombian medical center from 2007-2017. Int J Nephrol. 2018 Jun 28;2018:1-9. https://doi.org/10.1155/2018/9603453

Orozco JC, Restrepo AG, Gómez SP, Mora AM, Zapata DTS, Ríos JFN, et al. Proteinuria persistente en pacientes pediátricos, caracterización histopatológica y su influencia en la progresión de la enfermedad renal crónica. Med UPB. 2018 Jan;37(1):9-16. https://doi.org/10.18566/medupb.v37n1.a02

Arias LF, Henao J, Giraldo RD, Carvajal N, Rodelo J, Arbeláez M. Glomerular diseases in a Hispanic population: review of a regional renal biopsy database. Sao Paulo Med J. 2009;127(3):140-4. https://doi.org/10.1590/S1516-31802009000300006

Ballardie FW. IgA nephropathy treatment 25 years on: Can we halt progression? The evidence base. Nephrology Dialysis Transplantation Narnia; May 1, 2004 p. 1041-6. https://doi.org/10.1093/ndt/gfh208

Wang T, Ye F, Meng H, Zhang L, Jin X. Comparison of clinicopathological features between children and adults with IgA nephropathy. Pediatr Nephrol. 2012 Aug 5;27(8):1293-300. https://doi.org/10.1007/s00467-012-2139-3

Galla JH. IgA nephropathy. Kidney Int. 1995 Feb;47(2):377-87. https://doi.org/10.1038/ki.1995.50

Segarra A. Avances en el conocimiento de la patogenia de la nefropatía IgA: ¿nuevas perspectivas para un futuro inmediato? Vol. 30, Nefrologia. 2010. p. 501-7.

Bulut IK, Mir S, Sozeri B, Bulut MO, Sen S, Dincel N. Outcome results in children with IgA nephropathy: A single center experience. Int J Nephrol Renovasc Dis. 2012 Jan;5:23-8. https://doi.org/10.2147/IJNRD.S24684

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-14. https://dx.doi.org/10.1056/NEJMra1206793

Yu H-H, Chiang B-L. Diagnosis and classification of IgA nephropathy. Autoimmun Rev. 2014 May;13(4-5):556-9. https://doi.org/10.1016/j.autrev.2014.01.030

Hogg RJ, Silva FG, Wyatt RJ, Reisch JS, Argyle JC, Savino DA. Prognostic indicators in children with IgA nephropathy--report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1994 Feb;8(1):15-20. https://doi.org/10.1007/BF00868251

Coronel V, Mora-Orta S, Domínguez L, Corado J, Zibaoui PI, Bethencourt S, et al. [Clinical and pathological features in Venezuelan children with IgA nephropathy]. Invest Clin. 2007 Jun;48(2):167-74.

Kitagawa T. Lessons learned from the Japanese nephritis screening study. Pediatr Nephrol. 1988 Apr;2(2):256-63. https://doi.org/10.1007/BF00862602

Kamei K, Nakanishi K, Ito S, Ishikura K, Hataya H, Honda M, et al. Risk factors for persistent proteinuria after a 2-year combination therapy for severe childhood IgA nephropathy. Pediatr Nephrol. 2015 Jun;30(6):961-7. https://doi.org/10.1007/s00467-014-3019-9

Ronkainen J, Ala-Houhala M, Autio-Harmainen H, Jahnukainen T, Koskimies O, Merenmies J, et al. Long-term outcome 19 years after childhood IgA nephritis: A retrospective cohort study. Pediatr Nephrol. 2006 Sep 13;21(9):1266-73. https://doi.org/10.1007/s00467-006-0163-x

Mitsioni A. IgA nephropathy in children. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2001;16 Suppl 6:123-5. https://doi.org/10.1093/ndt/16.suppl_6.123

Fabiano RCG, Pinheiro SVB, Simões e Silva AC. Immunoglobulin A nephropathy: a pathophysiology view. Vol. 65, Inflammation Research. 2016. p. 757-70. https://doi.org/10.1007/s00011-016-0962-x

Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Vol. 140, Pediatrics. 2017. p. 1-72.

Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr. 1984 Jun;104(6):849-54. https://doi.org/10.1016/S0022-3476(84)80479-5

International Society of Nephrology. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2013;3(1):163.

Nakanishi K, Yoshikawa N. Immunoglobulin a nephropathies in children (includes HSP). In: Pediatric Nephrology, Seventh Edition. Berlin, Heidelberg: Springer Berlin Heidelberg; 2015. p. 983-1033. https://doi.org/10.1007/978-3-662-43596-0_28

Tanaka K, Moriyama T, Iwasaki C, Takei T, Nitta K. Effect of hematuria on the outcome of IgA nephropathy with mild proteinuria. Clin Exp Nephrol. 2015 Oct;19(5):815-21. https://doi.org/10.1007/s10157-014-1068-9

Restrepo de Rovetto C. Hematuria. In: ACONEPE (Asociación colombiana de nefrología pediátrica), editor. Enfoques en Nefrología pediátrica. 1st ed. Cali; 2009.

Coppo R. Corticosteroids in IgA Nephropathy: Lessons from Recent Studies. J Am Soc Nephrol JASN. 2017 Jan;28(1):25-33. https://doi.org/10.1681/ASN.2016060647

Davin JC, Ten Berge IJ, Weening JJ. What is the difference between IgA nephropathy and Henoch-Schönlein purpura nephritis? Kidney Int. 2001 Mar;59(3):823-34. https://doi.org/10.1046/j.1523-1755.2001.00565.x

Davin J-C. Henoch-Schonlein purpura nephritis: pathophysiology, treatment, and future strategy. Clin J Am Soc Nephrol CJASN. 2011 Mar;6(3):679-89. https://doi.org/10.2215/CJN.06710810

Selewski DT, Ambruzs JM, Appel GB, Bomback AS, Matar RB, Cai Y, et al. Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney Int Reports. 2018 Nov;3(6):1373-84.

Sozeri B, Mir S, Ertan P, Kara OD, Sen S. Rapidly progressive glomerulonephritis in a child with Henoch-Schönlein Vasculitis and familial Mediterranean fever. Pediatr Rheumatol. 2009 May 7;7:8. https://doi.org/10.1186/1546-0096-7-8

Donadio J, Larson TS, Bergstralh EJ, Grande JP. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol. 2001 Sep;12(4):791-9. https://doi.org/10.1681/ASN.V124791

Chan JCM, Trachtman H. Modulating the progression in IgA nephropathy. Nephron ClinPract. 2006;104(1):c61-68. https://dx.doi.org/10.1159/000093672

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA,et al.A Randomized,Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.J Am Soc Nephrol. 2017;28(4):1306-13. https://dx.doi.org/10.1681/ASN.2016060640

Trimarchi H, Barratt J, Monteiro RC, Feehally J. IgA nephropathy: “State of the art”: areport from the 15th International Symposium on IgA Nephropathy celebrating the 50thanniversary of its rst description. Kidney Int. 2019;95(4):750-6. https://dx.doi.org/10.1016/j.kint.2019.01.007

Vecchio M, Bonerba B, Palmer SC, Craig JC, Ruospo M, Samuels JA,et al.Immunosuppres-sive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2015;(8):CD003965.https://dx.doi.org/10.1002/14651858.CD003965.pub2

Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V,et al.Effect of oral methyl-prednisolone on clinical outcomes in patients with IgA nephropathy: The TESTING ran-domized clinical trial. JAMA. 2017;318(5):432-42. https://dx.doi.org/10.1001/jama.2017.9362

Higa A, Shima Y, Hama T, Sato M, Mukaiyama H, Togawa H,et al.Long-term outcome ofchildhood IgA nephropathy with minimal proteinuria. Pediatr Nephrol. 2015;30(12):2121-7.https://dx.doi.org/10.1007/s00467-015-3176-5

Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B,et al. Intensive SupportiveCare plus Immunosuppression in IgA Nephropathy. N Engl J Med. 2015;373(23):2225-36.https://dx.doi.org/10.1056/NEJMoa1415463

Chen Y, Li Y, Yang S, Li Y, Liang M. Ecacy and safety of mycophenolate mofetiltreatment in IgA nephropathy: a systematic review. BMC Nephrol. 2014;15(1):193. https://dx.doi.org/10.1186/1471-2369-15-193

Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE,et al.A randomizedtrial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis.Kidney Int. 1999;56(6):2220-6. https://dx.doi.org/10.1046/j.1523-1755.1999.00778.x

Liu X, Dewei D, Sun S, Xu G, Liu H, He L,et al.Treatment of severe IgA nephropathy:mycophenolate mofetil/prednisone compared to cyclophosphamide/prednisone. Int J ClinPharmacol Ther. 2014;52(2):95-102. https://dx.doi.org/10.5414/CP201887

Peng W, Tang Y, Jiang Z, Li Z, Mi X, Qin W. The effect of calcineurin inhibitors in thetreatment of IgA nephropathy: A systematic review and meta-analysis (PRISMA). Medicine(Baltimore). 2016;95(35):e4731. https://dx.doi.org/10.1097/MD.0000000000004731

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2020 Revista Colombiana de Nefrología




Download data is not yet available.